Cytokinetics, Incorporated (BIT:1CYTK)
Italy · Delayed Price · Currency is EUR 51.00
0.00 (0.00%)
At close: Oct 7, 2025
Cytokinetics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | -606.31 | -589.53 | -526.24 | -388.96 | -215.31 | -127.29 | Upgrade |
Depreciation & Amortization | 9.38 | 9.53 | 11.89 | 5.81 | 2.28 | 1.83 | Upgrade |
Stock-Based Compensation | 102.69 | 97.84 | 72.07 | 47.85 | 26.83 | 17.62 | Upgrade |
Other Adjustments | 72.03 | 50.6 | 24.87 | 60.48 | 35.23 | 31.89 | Upgrade |
Change in Receivables | -8.41 | -15.37 | -1.14 | 56.67 | -47.4 | 0.74 | Upgrade |
Changes in Accounts Payable | 4 | -4.48 | -3.48 | 4.52 | 1.06 | -0.11 | Upgrade |
Changes in Accrued Expenses | 15.21 | 14.18 | 17.1 | 10.84 | 15.06 | 7.12 | Upgrade |
Changes in Unearned Revenue | - | 52.37 | - | -87 | - | 87 | Upgrade |
Changes in Other Operating Activities | -16.85 | -11.04 | -9.4 | -9.74 | 39.74 | -9.85 | Upgrade |
Operating Cash Flow | -426.93 | -395.9 | -414.33 | -299.52 | -142.52 | 8.94 | Upgrade |
Capital Expenditures | -11.8 | -3.91 | -1.42 | -11.34 | -48.87 | -11.05 | Upgrade |
Purchases of Investments | -717.6 | -1,293 | -635.21 | -855.39 | -525.04 | -435.83 | Upgrade |
Proceeds from Sale of Investments | 953.05 | 744.23 | 875.88 | 604.59 | 426.14 | 250.36 | Upgrade |
Investing Cash Flow | 224.65 | -553.1 | 239.25 | -262.13 | -147.78 | -196.52 | Upgrade |
Long-Term Debt Issued | - | - | - | 523.59 | - | - | Upgrade |
Long-Term Debt Repaid | -11.39 | -9.62 | -0.86 | -188.93 | - | - | Upgrade |
Net Long-Term Debt Issued (Repaid) | -11.39 | -9.62 | -0.86 | 334.66 | - | - | Upgrade |
Issuance of Common Stock | 27.2 | 759.86 | 182.69 | 17.54 | 324.43 | 234.23 | Upgrade |
Repurchase of Common Stock | - | -19.63 | -10.52 | -9.6 | -4.45 | -2.26 | Upgrade |
Net Common Stock Issued (Repurchased) | 27.2 | 740.23 | 172.18 | 7.94 | 319.98 | 231.97 | Upgrade |
Other Financing Activities | - | 200 | 50 | 173.56 | - | 2.15 | Upgrade |
Financing Cash Flow | 89.1 | 930.61 | 221.32 | 516.17 | 319.98 | 234.12 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -0.79 | 0.21 | -0.02 | - | - | - | Upgrade |
Net Cash Flow | -113.97 | -18.17 | 46.22 | -45.48 | 29.68 | 46.55 | Upgrade |
Beginning Cash & Cash Equivalents | 190.52 | 113.4 | 67.18 | 112.67 | 82.99 | 36.43 | Upgrade |
Ending Cash & Cash Equivalents | 76.55 | 95.23 | 113.4 | 67.18 | 112.67 | 82.99 | Upgrade |
Free Cash Flow | -438.73 | -399.8 | -415.75 | -310.85 | -191.39 | -2.11 | Upgrade |
FCF Margin | - | -2164.13% | -5521.24% | -328.64% | -271.76% | -3.78% | Upgrade |
Free Cash Flow Per Share | -3.70 | -3.57 | -4.31 | -3.46 | -2.49 | -0.03 | Upgrade |
Levered Free Cash Flow | -617.77 | -542.49 | -512.4 | -141.19 | -206.06 | -52.36 | Upgrade |
Unlevered Free Cash Flow | -547.05 | -479.59 | -481.5 | -411.1 | -177.05 | -19.01 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.